Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- vibegron
- Xarelto (rivaroxaban)
Interactions between your drugs
rivaroxaban vibegron
Applies to: Xarelto (rivaroxaban), vibegron
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with vibegron may increase the plasma concentrations and effects of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. The exact mechanism for this interaction has not been established. When a single dose of vibegron (100 mg) was administered to healthy volunteers, the peak plasma concentration (Cmax) and systemic exposure (AUC) of the P-gp substrate digoxin increased by 21% and 11%, respectively. The risk of adverse reactions related to these substrates may be increased.
MANAGEMENT: Caution is advised if vibegron is coadministered with substrates of P-gp, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
VESIcare
Vesicare is used to treat symptoms of overactive bladder such as incontinence and frequent ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
Gemtesa
Gemtesa (vibegron) is used to treat overactive bladder symptoms (OAB) in adults or men taking ...
Estrace
Estrace (estradiol) is used to treat symptoms of menopause such as hot flashes and vaginal dryness ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Estradiol Patch
Estradiol Patch is used for atrophic urethritis, atrophic vaginitis, breast cancer, palliative ...
Vagifem
Vagifem vaginal inserts are used treat menopause symptoms such as dryness, burning, and irritation ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.